Company Overview
Sol-Gel Technologies Ltd. operates within the healthcare sector, specifically focusing on the biotechnology industry by developing and commercializing topical dermatological drugs for patients suffering from severe skin conditions. The company's operational footprint extends across multiple international markets including Israel, China, Switzerland, Canada, and the United States, where it offers products such as Twyneo, a once-daily, non-antibiotic topical treatment. In terms of scale, the company currently holds a market capitalization of $222.18M and employs a workforce of 28 individuals. Its reported trailing twelve-month revenue stands at $19.39M, figures that indicate a small-cap biotechnology entity with significant growth potential but limited current revenue base relative to its market valuation. The combination of a $222.18M market cap and under $20M in annual revenue suggests the company is in a development or early commercialization phase where market expectations are priced into the equity rather than current cash flows.
Financial Health
The company reported a revenue of $19.39M for the trailing twelve months, yet it generated a net income of $-6,127,000 and an EBITDA of $-7,483,000, revealing a substantial gap between top-line sales and bottom-line profitability that points to a high-cost operational structure typical of R-intensive biotechnology firms. Despite these operating losses, the company maintains a positive free cash flow of $617,000, which provides a degree of financial flexibility to fund ongoing research and development without immediate reliance on external capital markets. The margin profile is characterized by a gross margin of -17.6%, an operating margin of -497.8%, and a profit margin of -31.6%; the gross margin being negative indicates that the cost of goods sold currently exceeds the revenue generated from sales, while the deeply negative operating margin reflects significant overhead expenses relative to sales volume. On the liability side, the company holds $24.00M in cash against $991,000 in debt, resulting in a debt-to-equity ratio of 4.34, which presents a mixed picture of high leverage offset by a robust cash reserve that effectively mitigates immediate solvency risk. Liquidity is further supported by a current ratio of 4.37, indicating that the company possesses more than four times the current assets necessary to cover its short-term obligations, suggesting a strong ability to manage near-term financial commitments. However, the return on equity is recorded at -23.7% and the return on assets at -14.4%, metrics that reveal management is currently unable to generate positive returns on the capital invested or the assets deployed, a common characteristic for biotechnology companies prior to achieving commercial break-even.
Valuation Assessment
Valuation metrics for Sol-Gel Technologies Ltd. present a complex picture given the absence of positive earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -11.61, implying that the market is not valuing the stock based on current or near-term profitability but rather on future growth expectations or asset value. The price-to-book ratio stands at 9.66, indicating that the market values the company at a significant premium over its book value, a multiple often seen in biotechnology firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 11.46 and an EV/EBITDA of -26.62 suggest the market is willing to pay a high multiple for revenue generation despite the company's negative earnings before interest, taxes, depreciation, and amortization. The stock has exhibited high volatility, trading between a 52-week high of $97.97 and a 52-week low of $4.02, meaning the current price sits in a highly compressed range relative to its recent peak, reflecting the speculative nature of the investment. The beta value of 1.22 indicates that the stock is more volatile than the broader market, moving with greater intensity than the S&P 500 or similar indices, which amplifies price swings during periods of market stress or sector-specific news.
Growth & Income
The company demonstrates robust top-line expansion with a revenue growth rate of 150.4% year-over-year, whereas earnings growth is listed as N/A due to the absence of positive earnings in the prior period, implying that the rapid revenue increase has not yet translated into profitability. As a non-dividend payer, Sol-Gel Technologies Ltd. has a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all of its earnings and cash flow to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. The absence of a dividend program aligns with the strategic need for biotechnology firms to channel capital back into the pipeline to achieve regulatory approvals and product launches. The overall growth and income profile is defined by aggressive revenue expansion and total capital retention, prioritizing future market penetration over current income distribution to shareholders.